This is a randomized, open-label trial to assess the safety and efficacy of hydroxychloroquine, and zinc in combination with either azithromycin or doxycycline in a higher risk COVID-19 positive outpatient population.
COVID-19 is an aggressive and contagious virus, found to have high mortality especially in persons with comorbidities (Age\>60, hypertension \[HTN\], diabetes mellitus \[DM\], Cancer, and otherwise immunocompromised). Zinc is a supplement with possible antiviral properties, having been shown to have effect in the common cold, many of which are due to coronavirus. In addition, elderly patients and patients with co-morbidities have high incidence of zinc deficiency. We are repleting zinc in all patients and studying its direct effect in combination with hydroxychloroquine, and an antibiotic, either azithromycin or doxycycline to see if there is enhanced treatment efficacy in early COVID-19 infection and assess the safety of these two regimen.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
18
Hydroxychloroquine 400mg twice a day (BID) on day 1, followed by 200mg BID for days 2-5
Azithromycin 500mg on day 1, followed by 250mg once daily for days 2-5
Zinc sulfate 220mg once daily for 5 days
St Francis Hospital
Roslyn, New York, United States
Time to Resolution of Symptoms relative to baseline (day 1 of trial)
Patients will be assessed on day 5 for when COVID-19 symptoms completely resolve compared to baseline (day 1 of trial)
Time frame: Day 5
Time to Resolution of Symptoms relative to baseline (day 1 of trial)
Patients will be assessed on day 14 for when COVID-19 symptoms completely resolve compared to baseline (day 1 of trial)
Time frame: Day 14
Time to Resolution of Symptoms relative to baseline (day 1 of trial)
Patients will be assessed on day 21 for when COVID-19 symptoms completely resolve compared to baseline (day 1 of trial)
Time frame: Day 21
Number of participants hospitalized and/or requiring repeat ER visits
Number of participants hospitalized and/or requiring repeat ER visits related to COVID-19 complications
Time frame: 21 days
ICU Length of Stay
If hospitalized, number of participants admitted to the ICU, and number of days in the ICU
Time frame: Until Discharged up to 30 days
Ventilator
If placed on ventilator, number of days on a ventilator
Time frame: Until extubated up to 30 days
Severity of symptoms
Severity of symptoms evaluated at day 5, day 14, and day 21 scored by the participant for feverishness, sore throat, cough, shortness of breath, myalgias. (0 =none; 1 = mild; 2 = moderate; 3 = severe)
Time frame: Day 5, Day 14, and Day 21
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Doxycycline 200 mg once daily for 5 days
Number of participants with adverse events due to drug regimen
Number of participants with adverse events due to drug regimen
Time frame: 21 days
Number of participants with QTc prolongation >500ms
Assess all patients to evaluate for QTc prolongation \>500ms
Time frame: Days 1 thru 5, Day 10, Day 21